Want to see SION full AI Analyst Report?
SION Stock Chart & Stats
$45.70
$1.64(3.72%)
At close: 4:00 PM EDT
$45.70
$1.64(3.72%)
Day’s Range― - ―
52-Week Range$4.01 - $54.97
Previous CloseN/A
Volume654.94K
Average Volume (3M)433.16K
Market Cap
$239.17M
Enterprise Value$1.78K
Total Cash (Recent Filing)$211.03M
Total Debt (Recent Filing)$8.07M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 11, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding45,212,400
10 Day Avg. Volume474,586
30 Day Avg. Volume433,158
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.17Price Target Upside-66.81% Downside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits mandatory financing costs and preserves financial flexibility. The sizeable equity base relative to debt gives Sionna more capacity to fund research, manage setbacks, and pursue strategic options.
Cash ResourcesA substantial cash balance provides a meaningful development runway for the CF pipeline despite ongoing losses. Capital preservation can extend that runway and allow management to prioritize the most promising programs.
Phase 1 Pipeline ValidationSuccessful early safety and pharmacokinetic results, including selection of SION-451 plus SION-2222 as the preferred dual regimen, provide a clinically supported basis for continued pipeline development.
Bears Say
No RevenueSionna has no commercial revenue stream to offset research and development costs. This leaves long-term value dependent on clinical execution, future partnering, or product approval rather than established operating income.
Rising Cash BurnPersistent and increasing cash consumption means the company remains dependent on cash reserves or external financing. Continued spending without offsetting revenue could reduce strategic flexibility and increase future dilution risk.
Phase 2a FailureThe Phase 2a miss removes a development path intended to improve CFTR activity alongside existing treatment. Discontinuation narrows the pipeline and increases reliance on the earlier-stage SION-451 program.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $4.01 and its highest was $54.97 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $239.17M.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 79 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.01.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Overvalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.64.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 45,212,400 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went up 4.795%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.17 (-66.81% Downside)
$15.17 (-66.81% Downside)
Blogger Sentiment
Bullish
SION Sentiment 71%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 265.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.54%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$15.17
▼(-66.81% Downside)
Technical Analysis
Sarepta Therapeutics
―
Intellia Therapeutics
―
Stoke Therapeutics
―
Beam Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
33.56% Insiders
9.59% Mutual Funds
12.57% Other Institutional Investors
37.16% Public Companies and
Individual Investors